Floatz logo

mk-2206

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

203 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
Etoposide
Weill Medical College of Cornell University
Phase 2BBB
Lisaftoclax
Henan Cancer Hospital
Phase 3BBB
Chlorambucil
Ascentage Pharma Group Inc.
Phase 4BBB
Prednisone
AstraZeneca
Phase 3BBB
Irinotecan
IGM Biosciences, Inc.
Phase 2BBB

View all 50 →

Same molecule, other indications

mk-2206 is also rated in:

prostate cancerActive
B
Indicative · Phase 2
57 / 100
View asset →
breast carcinomaDormant
B
Indicative · Phase 2
57 / 100
View asset →
mantle cell lymphomaDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →